skip to main content

Valproate pregnancy prevention — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardAdverse Drug Reactions and Drug SafetyValproate pregnancy preventionGPhC CRA

A 28-year-old woman collects sodium valproate modified-release for bipolar disorder. She says she is not using contraception and is considering pregnancy within the next year. The prescription is from a mental health clinic, and there is no risk acknowledgement documentation in the pharmacy record. What is the most appropriate action?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Do not supply without urgent prescriber clarification of Pregnancy Prevention Programme requirements

Valproate is highly teratogenic and is subject to strict Pregnancy Prevention Programme requirements for people who can become pregnant. The stated pregnancy plans and absent documentation require urgent clarification before supply unless an emergency clinical risk assessment supports a limited supply. Folic acid does not remove the risk. Pharmacists should work with the specialist team to avoid abrupt unsafe changes while protecting pregnancy safety.

Reference: MHRA Valproate safety measures; BNF